Once-weekly oral islatravir-lenacapavir is noninferior to daily HIV therapy

Merck & Co. and Moderna Inc. reported positive results from a late-stage trial of their mRNA cancer vaccine, intismeran, combined with Keytruda, showing it delayed melanoma recurrence. Moderna's stock more than doubled on the news. The trial marks a significant step for cancer vaccines, though further research is needed for other cancer types. The companies did not disclose specific efficacy data.

Gilead Sciences and Merck reported positive phase 3 trial results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. The ISLEND-1 and ISLEND-2 trials showed the regimen maintained virologic suppression comparable to daily treatments, with 0% and 0.3% of participants having HIV-1 RNA levels above 50 copies/mL, respectively. The companies plan to submit these findings for regulatory review.

Merck (MRK) and Moderna (MRNA) announced positive Phase 3 trial results for their personalized cancer vaccine, Intismeran, in combination with Keytruda for melanoma. Merck's shares surged 12.5%, adding $43 billion to its market value. Analysts raised price targets, citing the vaccine's potential to offset Keytruda's patent expiration in 2028. Goldman Sachs, UBS, and Bank of America increased their targets, while RBC Capital downgraded the stock.

Moderna (MRNA) and Merck (MRK) announced positive Phase 3 trial results for their personalized cancer vaccine, Intismeran, showing significant improvement in treating melanoma. Moderna's stock surged 177% in a single day. The companies are conducting further trials across various cancers. The treatment represents a breakthrough in personalized medicine, potentially leading to FDA approval.

Gilead Sciences (GILD) received European Commission approval for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for first-line metastatic triple-negative breast cancer (TNBC). The approval, based on Phase 3 study results, shows a 35% reduction in disease progression or death risk. Trodelvy is now established as a backbone therapy for TNBC across PD-L1 status. GILD stock closed at $146.12 on August 21, 2026, and is up 0.75% in pre-market trading.

Merck and Moderna's mRNA-based skin cancer vaccine showed promising results in a phase 3 trial with 1000 patients, according to Dr. Graham Unis of Providence Everett. The vaccine targets melanoma and may offer a significant leap forward in cancer treatment, with potential applications for other cancer types. The study suggests the vaccine could prevent recurrence and spread of melanoma, with results expected soon for other cancer trials.